Department of Chemistry and Biomolecular Sciences and Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW 2109, Australia.
J Proteome Res. 2013 Jun 7;12(6):2399-413. doi: 10.1021/pr3007182. Epub 2013 May 16.
Human plasma arguably represents the most comprehensive version of the human proteome. Despite its immense theoretical discovery potential, plasma has many high and medium abundance proteins that mask low abundance protein disease biomarkers of relevance, making the discovery of novel diagnostic markers particularly difficult. Some form of protein depletion and/or fractionation is essential in order to detect markers of low abundance. Here, we describe a "proof of concept" two-pronged approach to immunodeplete abundant proteins from human plasma. The method, called API (Abundant Protein Immunodepletion), involves the fractionation of plasma using dual ion exchange columns (protein repetitive orthogonal offline fractionation (PROOF)) to simplify the proteome, the production of polyclonal IgY against each fraction and finally using the purified antibodies in a immunodepletion column. We explored the use of this product for immunodepletion of human plasma and identified a total of 165 nonredundant proteins after depletion. Of these, 38 proteins that were not previously identified in nondepleted plasma were now detected. It is envisaged that further optimization of the method as well as its cyclic implementation (by reinjecting depleted plasma into chickens for second round of antibody production) can make this technology highly robust, extremely cost-effective, and ideal for high throughput biomarker discovery.
人血浆可以说是人类蛋白质组最全面的表现形式。尽管它具有巨大的理论发现潜力,但血浆中含有许多高丰度和中丰度的蛋白质,这些蛋白质掩盖了与疾病相关的低丰度蛋白质生物标志物,使得新的诊断标志物的发现变得特别困难。为了检测低丰度的标志物,某种形式的蛋白质耗竭和/或分级分离是必不可少的。在这里,我们描述了一种“概念验证”的双管齐下的方法,从人血浆中免疫耗竭丰富的蛋白质。该方法称为 API(丰富蛋白质免疫耗竭),涉及使用双离子交换柱(蛋白质重复正交离线分级分离(PROOF))对血浆进行分级分离,以简化蛋白质组,针对每个级分产生多克隆 IgY,最后在免疫耗竭柱中使用纯化的抗体。我们探索了该产品在人血浆免疫耗竭中的应用,在耗竭后总共鉴定出 165 种非冗余蛋白质。其中,有 38 种以前在未耗竭血浆中未鉴定到的蛋白质现在被检测到。预计该方法的进一步优化及其循环实施(通过将耗尽的血浆重新注入鸡中进行第二轮抗体生产)可以使该技术具有高度的稳健性、极高的成本效益,并且非常适合高通量生物标志物的发现。